## Belimumab (Benlysta) Treatment Plan

Patient Name:			DOB:	
Height (cm):		Weight (kg): _	Allergies:	
Diagnosis (select	t one):			
☐ M32.10 Systen	nic lupus e	erythematosus, organ or syst	em involvement unspecified	
☐ Other: ICD 10 (	Code:	Diagnosis	Description:	
Pre-Medications	: <u>:</u> **admir	nistered 30 minutes prior to	infusion**	
□ None				
☐ Acetaminophe	n 650 mg	PO		
☐ Diphenhydram	ine: Do	ose: 🗆 25 mg 🗆 50 mg	Route: $\square$ PO or $\square$ IVP	
☐ Methylprednis	olone: Do	ose: $\square$ 40 mg or $\square$ 125	Route: IVP	
☐ Famotidine:	Do	ose: 20 mg	Route: $\square$ PO or $\square$ IVPB	
$\square$ Other (include	drug, dos	e, and route):		
<b>Drug Orders:</b>				
• Belimumab (Be	enlysta) (J	0490) 10 mg/kg per 250 mL S	Sodium Chloride 0.9% IV to infuse over 1 I	nour
• Frequency:	Inductio	n: Weeks 0, 2, and 4 weeks t	then every 4 weeks thereafter	
☐ Maint		nance: every 4 weeks		
	Other: _			
Order Duration	ı: Six mon	ths unless otherwise specifie	d (Other:	)
Standing Orders	<u>:</u>			
		ol (CPOE-1396) will be activand physician notified.	ited if any hypersensitivity reaction occur	s, including anaphylaxis
Physician Signat	ure:		Date:	·
Physician Name:			Phone:	

## **Pre-Screening Requirements:**

• Provide positive autoantibody results (Anti-dsDNA, ANA, Anti-RNP, Anti-Smith)

## **Previous Therapies:**

with any questions.

For new patient referrals, please send history and physical and most recent physician note with completed plan
If patient has previously received belimumab at another facility, please provide last date received:
If patient has previously received another therapy (rituximab or cyclophosphamide), please provide the name: and the last date received:
nsurance/Authorization Information:
nsurance Type:
nsurance Authorization Reference Number:
Date Obtained: Authorization Valid Until:
Additional Notes:
Fax completed Treatment Plan with authorization information to McLeod Infusion Services at the number below or ca

Seacoast: 843-366-2224 (Fax)

843-366-3626 (Phone)